Nothing Special   »   [go: up one dir, main page]

MX2011008262A - Espiroamidas sustituidas como moduladores de b1r:. - Google Patents

Espiroamidas sustituidas como moduladores de b1r:.

Info

Publication number
MX2011008262A
MX2011008262A MX2011008262A MX2011008262A MX2011008262A MX 2011008262 A MX2011008262 A MX 2011008262A MX 2011008262 A MX2011008262 A MX 2011008262A MX 2011008262 A MX2011008262 A MX 2011008262A MX 2011008262 A MX2011008262 A MX 2011008262A
Authority
MX
Mexico
Prior art keywords
amides
substituted spiro
modulators
spiro
substituted
Prior art date
Application number
MX2011008262A
Other languages
English (en)
Inventor
Ruth Jostock
Stefan Schunk
Melanie Reich
Sabine Hees
Tieno Germann
Michael Franz-Martin Engels
Original Assignee
Gruenenthal Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gruenenthal Gmbh filed Critical Gruenenthal Gmbh
Publication of MX2011008262A publication Critical patent/MX2011008262A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La presente invención se relaciona con espiroamidas sustituidas, métodos para la producción de éstas, medicamentos conteniendo los compuestos referidos y el uso de espiroamidas sustituidas para la producción de medicamentos.
MX2011008262A 2009-02-06 2010-02-05 Espiroamidas sustituidas como moduladores de b1r:. MX2011008262A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09001659 2009-02-06
PCT/EP2010/000714 WO2010089127A1 (de) 2009-02-06 2010-02-05 Substituierte spiroamide als b1r-modulatoren

Publications (1)

Publication Number Publication Date
MX2011008262A true MX2011008262A (es) 2011-09-01

Family

ID=42111366

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011008262A MX2011008262A (es) 2009-02-06 2010-02-05 Espiroamidas sustituidas como moduladores de b1r:.

Country Status (12)

Country Link
US (1) US8357717B2 (es)
EP (1) EP2393812B1 (es)
JP (1) JP2012516864A (es)
AR (1) AR075052A1 (es)
AU (1) AU2010211215A1 (es)
BR (1) BRPI1008774A2 (es)
CA (1) CA2751535A1 (es)
ES (1) ES2429818T3 (es)
MX (1) MX2011008262A (es)
PL (1) PL2393812T3 (es)
TW (1) TW201030007A (es)
WO (1) WO2010089127A1 (es)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2816753A1 (en) 2010-11-08 2012-05-18 Lycera Corporation N- sulfonylated tetrahydroquinolines and related bicyclic compounds inhibition of rory activity and the treatment of diseases
US9302989B2 (en) 2010-11-15 2016-04-05 Abbvie Inc. NAMPT and rock inhibitors
HU1000676D0 (en) * 2010-12-17 2011-02-28 Pharmahungary 2000 Kft Inhibitors of matrix metalloproteinase, pharmaceutical compositions thereof and use of them for preventing and treating diseases where the activation of mmp is involved
US9657033B2 (en) 2012-05-08 2017-05-23 Lycera Corporation Tetrahydronaphthyridine and related bicyclic compounds for inhibition of RORγ activity and the treatment of disease
US9394315B2 (en) 2012-05-08 2016-07-19 Lycera Corporation Tetrahydro[1,8]naphthyridine sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease
TWI692469B (zh) 2012-11-09 2020-05-01 南韓商Ｌｇ化學股份有限公司 Ｇｐｒ４０受體促效劑，製造該促效劑的方法以及含有該促效劑作爲活性劑的醫藥組成物
EP2810931B1 (en) 2013-06-06 2018-04-25 Solvay SA Process for the preparation of halogenated carboxylic anhydrides
RU2720237C2 (ru) 2013-11-18 2020-04-28 Форма Терапеутикс, Инк. Композиции, содержащие бензопиперазин, в качестве ингибиторов бромодоменов вет
RS61519B1 (sr) 2013-11-18 2021-03-31 Forma Therapeutics Inc Sastavi tetrahidrohinolina kao inhibitori bet bromodomena
US9663502B2 (en) 2013-12-20 2017-05-30 Lycera Corporation 2-Acylamidomethyl and sulfonylamidomethyl benzoxazine carbamates for inhibition of RORgamma activity and the treatment of disease
WO2015095795A1 (en) 2013-12-20 2015-06-25 Merck Sharp & Dohme Corp. TETRAHYDRONAPHTHYRIDINE, BENZOXAZINE, AZA-BENZOXAZINE, AND RELATED BICYCLIC COMPOUNDS FOR INHIBITION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE
US9783511B2 (en) 2013-12-20 2017-10-10 Lycera Corporation Carbamate benzoxazine propionic acids and acid derivatives for modulation of RORgamma activity and the treatment of disease
WO2015131035A1 (en) 2014-02-27 2015-09-03 Lycera Corporation Adoptive cellular therapy using an agonist of retinoic acid receptor-related orphan receptor gamma & related therapeutic methods
CN104945416B (zh) * 2014-03-24 2017-11-17 中国科学院上海药物研究所 一类螺异噁唑啉衍生物、其制备方法及医药用途
EP3209641A4 (en) 2014-05-05 2018-06-06 Lycera Corporation Benzenesulfonamido and related compounds for use as agonists of ror and the treatement of disease
WO2015171610A2 (en) 2014-05-05 2015-11-12 Lycera Corporation Tetrahydroquinoline sulfonamide and related compounds for use as agonists of rory and the treatment of disease
MA40532A (fr) 2014-08-28 2021-04-28 Asceneuron Sa Inhibiteurs de glycosidases
AU2016219183B2 (en) 2015-02-11 2020-06-11 Merck Sharp & Dohme Corp. Substituted pyrazole compounds as RORgammaT inhibitors and uses thereof
AU2016257997A1 (en) 2015-05-05 2017-11-09 Lycera Corporation Dihydro-2H-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of RORy and the treatment of disease
CN107980042B (zh) 2015-06-11 2021-10-08 莱斯拉公司 用作RORγ激动剂和用于治疗疾病的芳基二氢-2H-苯并[b][1,4]噁嗪磺酰胺和相关化合物
CN105315126B (zh) * 2015-08-18 2018-01-23 巨化集团技术中心 一种2,3,3,3‑四氟丙烯制备方法
CA3002846A1 (en) 2015-10-27 2017-05-04 Merck Sharp & Dohme Corp. Substituted bicyclic pyrazole compounds as rorgammat inhibitors and uses thereof
WO2017075182A1 (en) 2015-10-27 2017-05-04 Merck Sharp & Dohme Corp. Substituted indazole compounds as rorgammat inhibitors and uses thereof
AU2016344118A1 (en) 2015-10-27 2018-05-10 Merck Sharp & Dohme Corp. Heteroaryl substituted benzoic acids as rorgammat inhibitors and uses thereof
WO2017144639A1 (en) 2016-02-25 2017-08-31 Asceneuron S. A. Glycosidase inhibitors
CN108884077A (zh) 2016-02-25 2018-11-23 阿森纽荣股份公司 糖苷酶抑制剂
US11261183B2 (en) 2016-02-25 2022-03-01 Asceneuron Sa Sulfoximine glycosidase inhibitors
EA201891438A1 (ru) 2016-02-25 2019-01-31 Асенейрон С. А. Кислотно-аддитивные соли производных пиперазина
AU2018216040A1 (en) * 2017-02-06 2019-06-20 Janssen Pharmaceutica Nv OGA inhibitor compounds
CA3067257A1 (en) 2017-06-22 2018-12-27 Curadev Pharma Limited Small molecule modulators of human sting
WO2018234807A1 (en) * 2017-06-22 2018-12-27 Curadev Pharma Limited HETEROCYCLIC MODULATORS WITH SMALL MOLECULES OF HUMAN STING
US20200138827A1 (en) * 2017-06-22 2020-05-07 Curadev Pharma Limited Small molecule modulators of human sting
US11213525B2 (en) 2017-08-24 2022-01-04 Asceneuron Sa Linear glycosidase inhibitors
CN108409649B (zh) * 2018-04-12 2021-05-04 苏州康润医药有限公司 一种5-溴-7-三氟甲基喹啉的合成方法
US12016852B2 (en) 2018-08-22 2024-06-25 Asceneuron Sa Pyrrolidine glycosidase inhibitors
WO2020039029A1 (en) 2018-08-22 2020-02-27 Asceneuron S. A. Spiro compounds as glycosidase inhibitors
US11795165B2 (en) 2018-08-22 2023-10-24 Asceneuron Sa Tetrahydro-benzoazepine glycosidase inhibitors
CN109020836A (zh) * 2018-09-06 2018-12-18 营创三征(营口)精细化工有限公司 一种氰乙酸乙酯的合成方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001278886A (ja) * 2000-03-28 2001-10-10 Dai Ichi Seiyaku Co Ltd ベンゾオキサジン誘導体及びこれを含有する医薬
DE102005016170A1 (de) 2005-04-07 2006-10-12 Grünenthal GmbH 4,5,6,7- Tetrahydro-isoxazolo(4,5c)pyridin-Verbindungen und deren Verwendung zur Herstellung von Arzneimitteln
CA2604920A1 (en) * 2005-04-15 2006-10-26 Elan Pharmaceuticals, Inc. Novel compounds useful for bradykinin b1 receptor antagonism
WO2007101007A2 (en) 2006-02-23 2007-09-07 Neurogen Corporation Aryl sulfonyl heterocycles
WO2007140383A2 (en) 2006-05-30 2007-12-06 Neurogen Corporation Spirocyclic sulfonamides and related compounds
WO2008033739A2 (en) * 2006-09-12 2008-03-20 Neurogen Corporation Benzimidazole carboxamide derivatives
EP2066659B1 (de) 2006-09-29 2013-08-28 Grünenthal GmbH Substituierte sulfonamid-derivate
WO2008046573A1 (de) 2006-10-16 2008-04-24 Grünenthal GmbH Substituierte sulfonamid-derivate als bradykinin 1 rezeptor modulatoren
EP2170350B1 (en) * 2007-06-21 2013-09-11 Cara Therapeutics, Inc. Substituted imidazoheterocycles

Also Published As

Publication number Publication date
PL2393812T3 (pl) 2013-12-31
BRPI1008774A2 (pt) 2016-03-08
US8357717B2 (en) 2013-01-22
JP2012516864A (ja) 2012-07-26
CA2751535A1 (en) 2010-08-12
ES2429818T3 (es) 2013-11-18
US20100234340A1 (en) 2010-09-16
EP2393812B1 (de) 2013-07-03
EP2393812A1 (de) 2011-12-14
AR075052A1 (es) 2011-03-02
WO2010089127A1 (de) 2010-08-12
AU2010211215A1 (en) 2011-09-29
TW201030007A (en) 2010-08-16

Similar Documents

Publication Publication Date Title
MX2011008262A (es) Espiroamidas sustituidas como moduladores de b1r:.
MX2011009369A (es) 2-mercaptoquinolin-3-carboxamidas sustituidas como moduladores de kcnq2/3.
MX2011008825A (es) 3-aminoisoxazolopiridinas sustituidas como moduladores de kcnq2/3.
MX2013003309A (es) Compuestos de benzamida sustituidos.
MX2011008864A (es) Tetrahidroazolopirazinas sulfoniladas y su uso como productos medicinales.
AU2010233994A8 (en) Bispecific anti-ErbB-3/anti-c-Met antibodies
MX2009003382A (es) Derivados de sulfonamidas sustituidos.
IN2012DN02984A (es)
MY170713A (en) Treatment protocol of diabetes type 2
MD20150091A2 (ro) Compuşi antivirali
MX340558B (es) Anticuerpos biespecificos que comprenden fragmento fv estabilizado con disulfuro.
MX336682B (es) Anticuerpos contra csf-1r humanos y usos de los mismos.
MX356337B (es) Anticuerpos contra csf-1r humano y sus usos.
MX2011008662A (es) 2-mercapto-3-aminopiridinas sustituidas como moduladores de kcnq2/3.
MX2011009338A (es) 3-amino-2-mercaptoquinolinas sustituidas como moduladores de kcnq2/3.
EA033455B1 (ru) Кристаллические формы замещенных 5-фтор-1h-пиразолопиридинов, способы их получения, их применение для получения лекарственного средства, лекарственное средство и способ лечения на их основе
IN2012DN00422A (es)
MX364069B (es) Moduladores de la proteína activadora de 5-lipoxigenasa.
NZ607149A (en) Galacto-oligosaccharide-containing composition and a method of producing it
MY156769A (en) Heat-aging-resistant polyamides
MX362689B (es) Procedimiento de preparacion de derivados de acido 3,5-bis(fluoroalquil)pirazol-4-carboxilico y 3,5-bis(fluoroalquil) pirazoles.
TN2012000610A1 (en) Heterocyclic compounds, their preparation and their therapeutic application
GEP201706626B (en) Synthesis of (s)-nifuratel
MY158910A (en) Surface modified silicic acid semi-gels
PH12017500270A1 (en) Use of 1-phenyl-3-dimethylaminopropane compounds for treating rheumatoid pain

Legal Events

Date Code Title Description
FG Grant or registration